Corteva vs Del Monte
CTVA and DMC side by side, both in consumer staples. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTVA and DMC compare
Corteva is the larger company, worth 6.2 times as much as Del Monte ($8.1B against $1.3B).
On earnings, Corteva is cheaper: it trades at 8.1× trailing earnings, against 16.2× for Del Monte.
Corteva grew revenue faster over the last twelve months (3.7% versus 1.4% for Del Monte).
Corteva keeps more of each dollar of sales as profit, with a net margin of 5.7% compared with 1.9% at Del Monte.
Both pay dividends: Corteva yields 5.9% and Del Monte 4.3%.
Corteva scores higher on the StockData Score (21 against 16 for Del Monte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTVA | DMC |
|---|---|---|
| Size and price | ||
| Market cap | $8.1B | $1.3B |
| Share price | $12.17 | $27.71 |
| Change, 1 year | −81.0% | −26.4% |
| Change, 5 years | −74.5% | 3.0% |
| Beta (5Y) | 0.64 | 0.29 |
| Employees | 22K | 6,088 |
| StockData Score | ||
| Total score | 21 (better) | 16 |
| Valuation score | 6 (better) | 4 |
| Growth score | 3 (better) | 1 |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 6 (better) | 3 |
| Valuation | ||
| P/E | 8.1× (better) | 16.2× |
| P/S | 0.5× | 0.3× (better) |
| P/B | 0.3× (better) | 0.6× |
| EV/EBITDA | 3.8× (better) | 8.9× |
| P/FCF | 12.9× | – |
| PEG | 19.18 | – |
| FCF yield | 7.7% (better) | −2.5% |
| Fair value | $55.12 | $39.56 |
| Margin of safety | 77.9% (better) | 30.0% |
| Growth | ||
| Revenue growth (TTM) | 3.7% (better) | 1.4% |
| Revenue growth, 5Y average | 4.1% (better) | 0.56% |
| Net income growth (TTM) | −28.0% | 2.8% (better) |
| EPS growth (TTM) | −26.3% | 4.9% (better) |
| EPS growth, 5Y average | 11.9% | 12.8% (better) |
| Profitability | ||
| Gross margin | 49.5% (better) | 9.6% |
| Operating margin | – | 2.9% |
| Net margin | 5.7% (better) | 1.9% |
| FCF margin | 3.5% (better) | −0.76% |
| Return on equity | 4.0% | 4.0% (better) |
| Return on invested capital | – | 4.0% |
| Financial health | ||
| Debt / equity | 0.19 (better) | 0.25 |
| Net debt / EBITDA | 0.89 (better) | 2.36 |
| Interest coverage | – | 7.5× |
| Current ratio | 1.52 | 2.30 (better) |
| Altman Z-score | 0.93 | 2.79 (better) |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | 5.9% (better) | 4.3% |
| Payout ratio | 48.0% | 69.8% |
| Years of dividend growth | 4 | 6 (better) |
| Dividend growth, 5Y average | 6.1% | 32.0% (better) |
| Buyback yield | 12.9% (better) | 2.7% |
| Shareholder yield | 18.9% (better) | 7.0% |
| Ownership | ||
| Held by institutions | 89.1% | 72.3% |
| Held by insiders | 0.27% | 54.6% |
| Insider net buying, 12 months | −$636K (better) | −$2.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.7% | 9.1% |
Go deeper
- CTVA stock overview
- CTVA income statement
- CTVA valuation and score
- DMC stock overview
- DMC income statement
- DMC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.